title: The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs.
abstract: In therapeutic drug monitoring (TDM) practice of psychotropic agents, it is common to summarize plasma concentrations of parent drugs and metabolites when these are considered equipotent. However, there is no clear definition of the term equipotent and one should be aware that metabolites referred to as equipotent in the literature could display several-fold differences in affinities toward target proteins. The fact that the parent drug and metabolite may have different abilities to penetrate the blood-brain-barrier further complicates the picture. Potential differences in brain distribution imply that various metabolite/drug ratios representing the same total concentration in plasma reflect different active concentrations in the brain. Plasma metabolite/drug ratios could differ extensively according to metabolic phenotype and administration route. An example is risperidone where the plasma metabolite/drug ratio is 30-fold lower in cytochrome P450 2D6 poor metabolizers compared to ultrarapid metabolizers, and four-fold lower after intramuscular compared to oral administration. As risperidone is more lipophilic and less effluxed by P-glycoprotein in the blood-brain-barrier than the active metabolite 9-hydroxyrisperidone, one might speculate that patients with high plasma metabolite/drug ratios obtain lower active concentrations in the brain. However, the relative drug-metabolite brain distribution needs to be quantified in humans to clarify to what degree drug and metabolite plasma levels reflect active brain concentrations. The present review illustrates the complexity of active metabolites in TDM with focus on amitriptyline, clomipramine, doxepin, imipramine, fluoxetine, venlafaxine and risperidone, all psychotropic drugs where target plasma concentration ranges are based on the sum of parent drug and metabolite. In addition, perspectives on the possibility of using distribution- and activity-weighted plasma concentrations are provided.
authors.affiliation: Department of Psychopharmacology, Diakonhjemmet Hospital, PO Box 85 Vinderen, 0319 Oslo, Norway. magnhild.hendset@diakonsyk.no
authors.forename: M
authors.initials: M
authors.lastname: Hendset
authors.forename: T
authors.initials: T
authors.lastname: Haslemo
authors.forename: I
authors.initials: I
authors.lastname: Rudberg
authors.forename: H
authors.initials: H
authors.lastname: Refsum
authors.forename: E
authors.initials: E
authors.lastname: Molden
mesh_terms: D001921:Brain / Q000378:metabolism*; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D007206:Individuality; D001523:Mental Disorders / Q000097:blood / Q000188:drug therapy; D011619:Psychotropic Drugs / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D011619:Psychotropic Drugs